Vanguard Group’s Aurinia Pharmaceuticals AUPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $23.1M | Sell |
1,449,884
-107,625
| -7% | -$1.53M | ﹤0.01% | 2550 |
|
|
2025
Q3 | $17.2M | Sell |
1,557,509
-163,369
| -9% | -$1.78M | ﹤0.01% | 2700 |
|
|
2025
Q2 | $14.6M | Sell |
1,720,878
-250,928
| -13% | -$2.01M | ﹤0.01% | 2712 |
|
|
2025
Q1 | $15.9M | Buy |
1,971,806
+241,858
| +14% | +$1.96M | ﹤0.01% | 2612 |
|
|
2024
Q4 | $15.5M | Buy |
1,729,948
+112,113
| +7% | +$915K | ﹤0.01% | 2714 |
|
|
2024
Q3 | $11.9M | Buy |
1,617,835
+78,723
| +5% | +$488K | ﹤0.01% | 2869 |
|
|
2024
Q2 | $8.79M | Buy |
1,539,112
+7,495
| +0.5% | +$39.5K | ﹤0.01% | 2997 |
|
|
2024
Q1 | $7.67M | Buy |
1,531,617
+21,119
| +1% | +$143K | ﹤0.01% | 3106 |
|
|
2023
Q4 | $13.6M | Buy |
1,510,498
+26,230
| +2% | +$216K | ﹤0.01% | 2786 |
|
|
2023
Q3 | $11.5M | Buy |
1,484,268
+101,751
| +7% | +$995K | ﹤0.01% | 2806 |
|
|
2023
Q2 | $13.4M | Buy |
1,382,517
+54,407
| +4% | +$565K | ﹤0.01% | 2787 |
|
|
2023
Q1 | $14.6M | Sell |
1,328,110
-46,413
| -3% | -$409K | ﹤0.01% | 2748 |
|
|
2022
Q4 | $5.94M | Buy |
1,374,523
+166,914
| +14% | +$969K | ﹤0.01% | 3220 |
|
|
2022
Q3 | $9.08M | Buy |
1,207,609
+38,652
| +3% | +$335K | ﹤0.01% | 2991 |
|
|
2022
Q2 | $11.7M | Buy |
1,168,957
+638,898
| +121% | +$7.14M | ﹤0.01% | 2907 |
|
|
2022
Q1 | $6.56M | Buy |
530,059
+110,354
| +26% | +$1.71M | ﹤0.01% | 3381 |
|
|
2021
Q4 | $9.6M | Buy |
419,705
+347,094
| +478% | +$8.22M | ﹤0.01% | 3231 |
|
|
2021
Q3 | $1.61M | Buy |
72,611
+75
| +0.1% | +$1.19K | ﹤0.01% | 4126 |
|
|
2021
Q2 | $940K | Sell |
72,536
-19,890
| -22% | -$253K | ﹤0.01% | 4165 |
|
|
2021
Q1 | $1.2M | Sell |
92,426
-2,728
| -3% | -$39.6K | ﹤0.01% | 3975 |
|
|
2020
Q4 | $1.32M | Buy |
95,154
+15,226
| +19% | +$222K | ﹤0.01% | 3763 |
|
|
2020
Q3 | $1.18M | Buy |
79,928
+22,626
| +39% | +$328K | ﹤0.01% | 3621 |
|
|
2020
Q2 | $931K | Sell |
57,302
-39,844
| -41% | -$638K | ﹤0.01% | 3631 |
|
|
2020
Q1 | $1.41M | Buy |
97,146
+49,197
| +103% | +$868K | ﹤0.01% | 3398 |
|
|
2019
Q4 | $971K | Buy |
47,949
+18,929
| +65% | +$174K | ﹤0.01% | 3649 |
|
|
2019
Q3 | $155K | Hold |
29,020
| – | – | ﹤0.01% | 3988 |
|
|
2019
Q2 | $191K | Buy |
29,020
+4,549
| +19% | +$29K | ﹤0.01% | 3984 |
|
|
2019
Q1 | $159K | Buy |
24,471
+9,700
| +66% | +$64.3K | ﹤0.01% | 3955 |
|
|
2018
Q4 | $101K | Hold |
14,771
| – | – | ﹤0.01% | 3998 |
|
|
2018
Q3 | $98K | Hold |
14,771
| – | – | ﹤0.01% | 4076 |
|
|
2018
Q2 | $83K | Hold |
14,771
| – | – | ﹤0.01% | 4068 |
|
|
2018
Q1 | $77K | Hold |
14,771
| – | – | ﹤0.01% | 4051 |
|
|
2017
Q4 | $67K | Buy |
+14,771
| New | +$82K | ﹤0.01% | 4022 |
|
Other funds holding AUPH
TCM
NMC
Vanguard Group's AUPH Position: Q4 2025 in Review
Vanguard Group reduced its Aurinia Pharmaceuticals (AUPH) stake by 6.9% in Q4 2025, selling an estimated $1.53M and leaving 1,449,884 shares worth $23.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2550.
Vanguard Group first reported a position in AUPH in Q4 2017 and has held it in 33 quarters since. 255 funds tracked by Wall St. Rank hold AUPH as of Q4 2025.
- Vanguard Group held 1,449,884 shares of Aurinia Pharmaceuticals worth $23.1M as of Q4 2025.
- Vanguard Group sold 107,625 Aurinia Pharmaceuticals shares in Q4 2025, an estimated $1.53M.
- Aurinia Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2550 holding.
- Vanguard Group first reported a position in Aurinia Pharmaceuticals in Q4 2017 and has held it in 33 quarters since.
- 255 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.